达雷妥尤单抗、来那度胺、硼替佐米和地塞米松用于适合移植的新诊断多发性骨髓瘤:GRIFFIN试验
GRIFFIN试验将207例适合移植的新诊断多发性骨髓瘤患者随机1:1分配至D-RVd或RVd组,比较诱导、移植、巩固及维持治疗。主要终点巩固后严格完全缓解率D-RVd组42.4% vs RVd组32.0%(OR 1.57,95%CI 0.87-2.82,单侧P=0.068),达到预设单侧α 0.10。中位随访22.1个月时D-RVd组严格完全缓解率62.6% vs 45.4%(P=0.0177),MRD阴性率51.0% vs 20.4%(P<0.0001)。
要点
- D-RVd方案加深了适合移植新诊断多发性骨髓瘤患者的缓解深度。
- D-RVd组3/4级血液学不良事件更常见,感染更多但3/4级感染率相似。
- D-RVd组CD34+细胞中位采集量8.2×10^6/kg,RVd组9.4×10^6/kg。
核心结论
- 达雷妥尤单抗联合RVd诱导和巩固治疗改善了适合移植新诊断多发性骨髓瘤患者的缓解深度,未出现新的安全性问题。
研究设计与样本
- 随机、开放标签、1:1分配的GRIFFIN试验,纳入207例适合移植的新诊断多发性骨髓瘤患者。
- 患者接受4周期D-RVd或RVd诱导、自体造血干细胞移植、2周期D-RVd或RVd巩固,以及来那度胺或来那度胺联合达雷妥尤单抗维持治疗26周期。
主要发现
- 主要终点巩固后严格完全缓解率D-RVd组42.4% vs RVd组32.0%(OR 1.57,95%CI 0.87-2.82,单侧P=0.068),达到预设单侧α 0.10。
- 中位随访22.1个月时,严格完全缓解率D-RVd组62.6% vs RVd组45.4%(P=0.0177)。
- 意向治疗人群MRD阴性率(10^-5阈值)D-RVd组51.0% vs RVd组20.4%(P<0.0001)。
- D-RVd组4例(3.8%)vs RVd组7例(6.8%)疾病进展,24个月无进展生存率分别为95.8%和89.8%。
- D-RVd组3/4级血液学不良事件更常见,感染更多但3/4级感染率相似;CD34+细胞中位采集量D-RVd组8.2×10^6/kg vs RVd组9.4×10^6/kg,D-RVd组使用普乐沙福更常见;中性粒细胞和血小板植入中位时间相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lenalidomide, bortezomib, and dexamethasone (RVd) followed by autologous stem cell transplantation (ASCT) is standard frontline therapy for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). The addition of daratumumab (D) to RVd (D-RVd) in transplant-eligible NDMM patients was evaluated. Patients (N = 207) were randomized 1:1 to D-RVd or RVd induction (4 cycles), ASCT, D-RVd or RVd consolidation (2 cycles), and lenalidomide or lenalidomide plus D maintenance (26 cycles). The primary end point, stringent complete response (sCR) rate by the end of post-ASCT consolidation, favored D-RVd vs RVd (42.4% vs 32.0%; odds ratio, 1.57; 95% confidence interval, 0.87-2.82; 1-sided P = .068) and met the prespecified 1-sided α of 0.10. With longer follow-up (median, 22.1 months), responses deepened; sCR rates improved for D-RVd vs RVd (62.6% vs 45.4%; P = .0177), as did minimal residual disease (MRD) negativity (10-5 threshold) rates in the intent-to-treat population (51.0% vs 20.4%; P < .0001). Four patients (3.8%) in the D-RVd group and 7 patients (6.8%) in the RVd group progressed; respective 24-month progression-free survival rates were 95.8% and 89.8%. Grade 3/4 hematologic adverse events were more common with D-RVd. More infections occurred with D-RVd, but grade 3/4 infection rates were similar. Median CD34+ cell yield was 8.2 × 106/kg for D-RVd and 9.4 × 106/kg for RVd, although plerixafor use was more common with D-RVd. Median times to neutrophil and platelet engraftment were comparable. Daratumumab with RVd induction and consolidation improved depth of response in patients with transplant-eligible NDMM, with no new safety concerns. This trial was registered at www.clinicaltrials.gov as #NCT02874742.
引用
- Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020. PMID: 32325490. doi:10.1182/blood.2020005288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。